Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINT-2: Boceprevir in untreated chronic hepatitis C
NCT00705432Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2008
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of boceprevir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoint: Sustained Virologic Response Rate. Started Aug 2008; status: completed.
02
Drugs
boceprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00705432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705432.